This Program Project is organized along the common theme of increasing the immune response to human tumors by genetic engineering of tumor cells or immune effector cells. We propose to determine whether cytokine-transduced human tumors generate an immune response in vivo. To accomplish this, we propose a clinical vaccine trials for 2 solid tumors - melanoma, neuroblastoma - 4 different cytokines - IL-2, IL-7, gammaIFN, alphaIFN. Coordinated by a Vaccine Core and a Clinical Immunology Core, similar protocol design and clinical testing will allow a comparison of cytokines and tumors and allow us to refine gene therapy strategies. Using recombinant adenovirus vectors, we propose to develop improved strategies for cytokine-based vaccines. We will determine whether these high efficiency vectors can optimize ex vivo or in vivo gene delivery to tumors. Finally, we propose to develop a novel method for delivery of gene- engineered proteins to tumors by targeting proteins to granules of TIL. We will identify the """"""""targeting peptide motif"""""""" that can direct proteins to cytotoxic granules and determine whether gene-engineered TIL will release the introduced protein only when specifically triggered by interaction with tumor targets. In summary, a Program Project is proposed that quickly brings several vaccine protocols to clinical trial and provides for the testing of novel strategies of tumor and cytotoxic lymphocyte gene transfer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059326-06
Application #
2633846
Study Section
Special Emphasis Panel (SRC (DD))
Program Officer
Xie, Heng
Project Start
1992-09-30
Project End
1998-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Surgery
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Chen, R L; Reynolds, C P; Seeger, R C (2000) Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 48:603-12
Penichet, M L; Challita, P M; Shin, S U et al. (1999) In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 49:179-88
Kutubuddin, M; Federoff, H J; Challita-Eid, P M et al. (1999) Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93:643-54
Challita-Eid, P M; Abboud, C N; Morrison, S L et al. (1998) A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol 161:3729-36
Shau, H; Huang, A C; Faris, M et al. (1998) Thioredoxin peroxidase (natural killer enhancing factor) regulation of activator protein-1 function in endothelial cells. Biochem Biophys Res Commun 249:683-6
Challita-Eid, P M; Penichet, M L; Shin, S U et al. (1998) A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol 160:3419-26
Shau, H; Kim, A T; Hedrick, C C et al. (1997) Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses. Free Radic Biol Med 22:497-507
Kim, A T; Sarafian, T A; Shau, H (1997) Characterization of antioxidant properties of natural killer-enhancing factor-B and induction of its expression by hydrogen peroxide. Toxicol Appl Pharmacol 147:135-42
Syljuasen, R G; Belldegrun, A; Tso, C L et al. (1997) Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection. Radiat Res 148:443-8
Arthur, J F; Butterfield, L H; Roth, M D et al. (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17-25

Showing the most recent 10 out of 31 publications